On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of its 4.950% notes due September 19, 2029. The company intends to use the net proceeds from this issuance, combined with existing cash on hand, to repay $500 million in outstanding principal of its 4.650% notes maturing on September 9, 2026. This refinancing activity involves significant debt restructuring and capital management. Illumina operates in the life sciences industry, specializing in genomic sequencing technologies.
